Skip to main content

Table 4 WST-1 proliferation assay for BT474 cells treated with atRA, trastuzumab, and tamoxifen

From: Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations

 

Fraction affected

 

Dose

atRA

Trastuzumab

Tamoxifen

atRA + Tzmab + Tam

Combination index

0.2

0.20 ± 0.028

0.24 ± 0.017

0.10 ± 0.063

0.58 ± 0.017

0.15 ± 0.014

0.4

0.29 ± 0.041

0.48 ± 0.032

0.15 ± 0.036

0.84 ± 0.007

0.01 ± 0.001

0.6

0.37 ± 0.023

0.58 ± 0.012

0.25 ± 0.087

0.89 ± 0.010

0.01 ± 0.001

1

0.46 ± 0.046

0.63 ± 0.023

0.29 ± 0.055

0.90 ± 0.006

0.01 ± 0.003

5

0.55 ± 0.038

0.65 ± 0.015

0.37 ± 0.055

0.89 ± 0.009

0.06 ± 0.011

10

0.57 ± 0.041

0.66 ± 0.030

0.59 ± 0.048

0.90 ± 0.003

0.09 ± 0.020

  1. Doses of all-trans retinoic acid (atRA), trastuzumab (Tzmab), and tamoxifen (Tam) in μM, μg/ml, and μM, respectively. Each value is the mean of three independent experiments (with eight replicate wells for each treatment) ± standard error.